Global GLP-1/GIP Dual Receptor Agonist Supply, Demand and Key Producers, 2026-2032
The global GLP-1/GIP Dual Receptor Agonist market size is expected to reach $ 70279 million by 2032, rising at a market growth of 10.7% CAGR during the forecast period (2026-2032).
In 2025, global GLP-1/GIP Dual Receptor Agonist production reached approximately 188.95 M Units, with an average global market price of around 175.26 USD per Unit.
A GLP-1/GIP dual receptor agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity.To date, Tirzepatide is the only commercially available GLP-1/GIP dual receptor agonist product in the world.
GLP-1/GIP dual receptor agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma’s most strategically important therapeutic area.
The upstream raw materials for GLP-1/GIP Dual Receptor Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.
The single-line production capacity of GLP-1/GIP dual receptor agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.
This report studies the global GLP-1/GIP Dual Receptor Agonist production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for GLP-1/GIP Dual Receptor Agonist and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of GLP-1/GIP Dual Receptor Agonist that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global GLP-1/GIP Dual Receptor Agonist total production and demand, 2021-2032, (K Units)
Global GLP-1/GIP Dual Receptor Agonist total production value, 2021-2032, (USD Million)
Global GLP-1/GIP Dual Receptor Agonist production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global GLP-1/GIP Dual Receptor Agonist consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: GLP-1/GIP Dual Receptor Agonist domestic production, consumption, key domestic manufacturers and share
Global GLP-1/GIP Dual Receptor Agonist production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global GLP-1/GIP Dual Receptor Agonist production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global GLP-1/GIP Dual Receptor Agonist production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global GLP-1/GIP Dual Receptor Agonist market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GLP-1/GIP Dual Receptor Agonist market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global GLP-1/GIP Dual Receptor Agonist Market, By Region:
1. How big is the global GLP-1/GIP Dual Receptor Agonist market?
2. What is the demand of the global GLP-1/GIP Dual Receptor Agonist market?
3. What is the year over year growth of the global GLP-1/GIP Dual Receptor Agonist market?
4. What is the production and production value of the global GLP-1/GIP Dual Receptor Agonist market?
5. Who are the key producers in the global GLP-1/GIP Dual Receptor Agonist market?
6. What are the growth factors driving the market demand?
In 2025, global GLP-1/GIP Dual Receptor Agonist production reached approximately 188.95 M Units, with an average global market price of around 175.26 USD per Unit.
A GLP-1/GIP dual receptor agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity.To date, Tirzepatide is the only commercially available GLP-1/GIP dual receptor agonist product in the world.
GLP-1/GIP dual receptor agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma’s most strategically important therapeutic area.
The upstream raw materials for GLP-1/GIP Dual Receptor Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.
The single-line production capacity of GLP-1/GIP dual receptor agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.
This report studies the global GLP-1/GIP Dual Receptor Agonist production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for GLP-1/GIP Dual Receptor Agonist and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of GLP-1/GIP Dual Receptor Agonist that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global GLP-1/GIP Dual Receptor Agonist total production and demand, 2021-2032, (K Units)
Global GLP-1/GIP Dual Receptor Agonist total production value, 2021-2032, (USD Million)
Global GLP-1/GIP Dual Receptor Agonist production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global GLP-1/GIP Dual Receptor Agonist consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: GLP-1/GIP Dual Receptor Agonist domestic production, consumption, key domestic manufacturers and share
Global GLP-1/GIP Dual Receptor Agonist production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global GLP-1/GIP Dual Receptor Agonist production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global GLP-1/GIP Dual Receptor Agonist production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global GLP-1/GIP Dual Receptor Agonist market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GLP-1/GIP Dual Receptor Agonist market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global GLP-1/GIP Dual Receptor Agonist Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Balanced
- Biased
- Others
- Balanced
- Biased
- Others
- Long-acting
- Short-acting
- Diabetes
- Obesity
- Others
- Eli Lilly
- Roche
- Viking Therapeutics
- Ascletis Pharma
- Jiangsu Hengrui Medicine
- East China Pharmaceutical
- Tonghua Dongbao Pharmaceutical
- Lepu Medical Technology
- Hansoh Pharma
1. How big is the global GLP-1/GIP Dual Receptor Agonist market?
2. What is the demand of the global GLP-1/GIP Dual Receptor Agonist market?
3. What is the year over year growth of the global GLP-1/GIP Dual Receptor Agonist market?
4. What is the production and production value of the global GLP-1/GIP Dual Receptor Agonist market?
5. Who are the key producers in the global GLP-1/GIP Dual Receptor Agonist market?
6. What are the growth factors driving the market demand?
